New NIBR President Jay Bradner shares on drug discovery, his leadership style and what’s next for his career in biomedical research.

An essay by Vas Narasimhan, CEO of Novartis about the historical context and coming innovations in medicine with an introduction by Goran Mijuk.

What happens when a patient’s only treatment hope rests with a promising but not yet locally approved therapy? At Novartis, we are providing a lifeline of access to innovative medicines under review or not yet approved locally when no other treatment options are available.

The leaders behind the Novartis Innovation Lab share how they are leveraging emerging technologies to win for patients.

Experimental treatments for Alzheimer’s disease put the amyloid cascade hypothesis to the test.

One man’s fascination with malaria helps fuel the search for new treatments.